CIK 0001400118 · <br>Emerging growth company
Sagimet Biosciences Inc.
Sign in to watch- Ticker
- SGMT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205991472
- Phone
- (650) 561-8600
- Business address
- 950 TOWER LANE, STE 1500, FOSTER CITY, CA, 94404
- Former names
- 3-V Biosciences, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-28 | Grauer Andreas Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +35,000 | 35,000 | ||
| 2026-05-28 | Rozek Elizabeth Chief Legal & Admin. Officer | Grant or award · Stock Option (Right to Buy) | +100,000 | 100,000 | ||
| 2026-05-28 | Happel David President & CEO | Grant or award · Stock Option (Right to Buy) | +300,000 | 300,000 | ||
| 2026-04-20 | Grauer Andreas Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +264,759 | 264,759 | ||
| 2026-02-19 | Rozek Elizabeth Chief Legal & Admin. Officer | Grant or award | +44,000 | 234,959 | ||
| 2026-02-19 | Rozek Elizabeth Chief Legal & Admin. Officer | Grant or award · Stock Option (Right to Buy) | +88,000 | 88,000 | ||
| 2026-02-19 | Martins Eduardo Bruno Chief Medical Officer | Grant or award | +44,000 | 147,296 | ||
| 2026-02-19 | Martins Eduardo Bruno Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +88,000 | 88,000 | ||
| 2026-02-19 | Happel David President & CEO | Grant or award | +128,000 | 805,621 | ||
| 2026-02-19 | Happel David President & CEO | Grant or award · Stock Option (Right to Buy) | +256,000 | 256,000 | ||
| 2026-02-19 | Chauche Thierry Chief Financial Officer | Grant or award | +44,000 | 59,688 | ||
| 2026-02-19 | Chauche Thierry Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +88,000 | 88,000 | ||
| 2026-02-10 | Happel David President & CEO | Sale | −12,101 | $5.36 | $65K | 677,621 |
| 2026-02-10 | Chauche Thierry Chief Financial Officer | Sale | −1,312 | $5.36 | $7K | 15,688 |
| 2026-02-10 | Martins Eduardo Bruno Chief Medical Officer | Sale | −3,640 | $5.36 | $20K | 103,296 |
| 2026-02-10 | Rozek Elizabeth Chief Legal & Admin. Officer | Sale | −2,622 | $5.36 | $14K | 190,959 |
| 2025-11-20 | Kemble George Executive Chairman | Sale 10b5-1 | −37,688 | $7.69 | $290K | 81,005 |
| 2025-11-04 | Rozek Elizabeth Chief Legal & Admin. Officer | Grant or award | +9,855 | 193,581 | ||
| 2025-11-04 | Rozek Elizabeth Chief Legal & Admin. Officer | Grant or award · Stock Option (Right to Buy) | +13,367 | 13,367 | ||
| 2025-07-21 | Happel David President & CEO | Sale | −65,478 | $9.13 | $598K | 689,722 |
Page 2 of 10 · 194 trades